News
Hosted on MSN1mon
Bayer's sNDA for Kerendia Label Expansion Gets FDA's Priority ReviewPer management, finerenone is the first drug targeting the mineralocorticoid receptor pathway which has shown cardiovascular benefits in a phase III study for treating HF with an LVEF of ≥40%.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback